Large cohort study reveals treatment response variability for IL-17 inhibitors in psoriasis, indicating factors affecting effectiveness.
Overall, IL-17 inhibitors show substantial efficacy and a favorable safety profile for psoriasis in special sites, with treatment response variability influenced primarily by baseline clinical characteristics such as BMI and disease severity indices.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: